OR WAIT null SECS
A collaborative pharmaceutical project to develop paediatric formulations using smart design and predictive science has received the go ahead after securing a ?660,000 grant from UK-based Technology Strategy Board.
A collaborative pharmaceutical project to develop paediatric formulations using smart design and predictive science has received the go ahead after securing a £660,000 grant from UK-based Technology Strategy Board. The £1 million project seeks to improve the speed, cost and quality of paediatric formulation development by drawing on the combined expertise of consortium members. The UK consortium is lead by Astra Zeneca and comprises of Molecular Profiles alongside Pfizer, Bristol Myers Squibb, GlaxoSmithKline and academic institutions including University College London, University of Bath, University of Birmingham, Aston University and the Academy of Pharmaceutical Sciences, a nonprofit organization.
As the development paediatric formulations must take into account the physiology and anatomy differences in children, these medicines are more complex to develop. Moreover paediatric formulations must offer flexible dosing and provide effective taste-masking.
The project aims is to develop a novel, commercially available, regulatory-approved platform to identify the most appropriate delivery strategy. Molecular Profiles' chief executive officer Nikin Patel said in a press release that the project is an ambitious venture and that receipt of the Technology Strategy Board grant will enable the project to move forward with this multi-partner project.
Source: Molecular Profiles